No Data
Rigel to Present at the 2024 Cantor Global Healthcare Conference
Express News | Rigel Announces First Patient Enrolled in Phase 1B/2 Triplet Therapy Trial of Rezlidhia® (Olutasidenib) in Midh1 Aml
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (Olutasidenib) in MIDH1 AML
Express News | Kissei Pharmaceutical Co Ltd - Licensing Agreement for "Olutasidenib", an Acute Myeloid Leukemia Drug
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
Express News | Rigel Pharmaceuticals- to Get Product Transfer Price Payments in Mid-20 to Lower-30% Range Based on Tiered Net Sales for Exclusive Supply of Rezlidhia